Cutting Through all the Noise at Retrophin
I have to admit to a dilemma. Since purchasing a little over 1% fully-diluted of Retrophin, Inc. (Nasdaq: RTRX) last summer in the $4.50/sh PIPE and subsequently tweeting about the company, I’ve built up quite a number of readers who look to me for advice and analysis regarding Retrophin.
Since I and my family still own a very significant stake in the company, it would be unwise of me to write research on the company without highly qualifying my opinions as coming from someone who is deeply conflicted given our exposure to the equity. On the other hand, with Retrophin’s stock hitting all-time highs last week, it’s understandable why so many of my readers have reached out to me asking if now is the time to sell.
Like I have said numerous times, I cannot and will not give individual investment advice. However, I do believe readers of mine who have purchased Retrophin deserve to hear from me with an updated report summarizing my investment viewpoint on the company.
I have always said that Retrophin should be viewed as a “biotech hedge fund” with a hodge-podge of disparate assets. Some of these assets are very high risk and others much lower risk; the common thread is that the potential upside of the pipeline far outweighs the cash needed to push these products through clinical trials and into the marketplace.
With that in mind, I have written a piece analyzing the sum of the parts. In order that this research not be viewed as an attempt to create a frenzy in the market, I have password-protected the piece, for download only to my readership. If you wish to unlock the report, please email me a request for the password, acknowledging the following : (a) you are not relying on any information contained herein solely for the purposes of investing in Retrophin common stock; (b) you will not disseminate this research report to anyone and that you are downloading it solely for your own use; (c) you acknowledge that the author of this report and his family are directly and indirectly own shares of Retrophin and therefore the opinions contained herein cannot be viewed as free of any conflicts of interest.
Readers : Email me (using the email address at the top of this page) that you agree to the above, and you will get the password to the research report sent to you, which can be downloaded here : Cutting Through all the Noise at Retrophin